A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical trial NCT01611090 · COMPLETED
Trial details
- NCT number
- NCT01611090
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-19
- Primary completion
- 2019-01-23
- Enrollment
- 578
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.